A Single Patient Protocol for TNB-383B, a Bispecific Antibody Targeting BCMA in a Subject With Relapsed/Refractory Multiple Myeloma


This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma who is not a candidate for treatment regimens known to provide clinical benefit in multiple myeloma.

SparkCures ID 1084
Trial Phase Expanded Access
Enrollment Information Not Available
Trial Sponsors
  • Teneobio Inc.
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Adequate bone marrow function
  • eGFR ≥ 30 mL/min
  • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
  • Serum calcium (corrected for albumin) at or below the ULN range

Exclusion Criteria:

  • Candidate for treatment regimens known to provide clinical benefit in MM
  • Active infection requiring parenteral anti-infective treatment
  • Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers